Forvisirvat

Forvisirvat (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name SP-624) is a sirtuin-6 (SIRT6) activator which is under development for the treatment of major depressive disorder and schizophrenia.^{[1][2][3][4][5]} It is taken by mouth.^[1] As of January 2025, forvisirvat is in phase 2/3 clinical trials for major depressive disorder and is in phase 1/2 clinical trials for schizophrenia.^[1][2][4] It is under development by Sirtsei Pharmaceuticals and Arrivo BioVentures.^[1][2][5]

Forvisirvat

Clinical data
Other names	SP624
Routes of administration	Oral[1]
Drug class	Sirtuin-6 (SIRT6) activator[1]
Identifiers
IUPAC name (2S,5'R)-7-chloro-3',4-dimethoxy-5'-methyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)spiro[1-benzofuran-2,4'-cyclohex-2-ene]-1',3-dione
CAS Number	2135638-06-9
PubChem CID	131964504
ChemSpider	129910029
Chemical and physical data
Formula	C19H17ClN2O6
Molar mass	404.80 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(C=C(C(=C3O2)Cl)C4=NN=C(O4)C)OC)OC
InChI InChI=1S/C19H17ClN2O6/c1-8-5-10(23)6-13(26-4)19(8)17(24)14-12(25-3)7-11(15(20)16(14)28-19)18-22-21-9(2)27-18/h6-8H,5H2,1-4H3/t8-,19+/m1/s1 Key:MIHSWFYCAJWPIS-YLVJLNSGSA-N

See also

• List of investigational antidepressants
• List of investigational antipsychotics